John A. Glaspy
University of California, Los Angeles · 727 works · 38,704 citations · h-index 90
Top works
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
- Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206
- Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- Cancer Detection with Whole-Body PET Using 2-[18F]Fluoro-2-Deoxy-D-Glucose
- Current Developments in Cancer Vaccines and Cellular Immunotherapy
- Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy?
- Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.
- Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer
- Thrombocytopenia caused by the development of antibodies to thrombopoietin
- Results of a multicenter, randomized, double‐blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma
- The Application of Positron Emission Tomographie Imaging With Fluorodeoxyglucose to the Evaluation of Breast Disease
- Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose
- Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
- Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
- The role of positron emission tomography in oncology and other whole-body applications